CorMedix Inc.

Drug pipeline (4)

Asset	Stage	Revenue	Trials	Status
TAUROLIDINE	approved	$258.8MFY 2025	0	—
DELAFLOXACIN MEGLUMINE	approved	—	0	—
Metoprolol Succinate	approved	—	2	approved
ORITAVANCIN DIPHOSPHATE	approved	—	0	—

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (5)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT06822426	phase3	recruiting	2025-05-14	2028-01-01	CorMedix Therapeutics	Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
NCT01146925	phase2	completed	2010-06-01	2011-06-01	CorMedix Therapeutics	Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
NCT01391520	phase3	withdrawn	2012-01-01	2013-03-01	CorMedix Therapeutics	Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent
NCT06714864	phase4	recruiting	2025-07-08	2028-07-01	CorMedix Therapeutics	Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age
NCT02651428	phase3	completed	2015-12-01	2018-10-01	CorMedix Therapeutics	Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection

FDA applications (6)

Application

Approved

Type

Applicant

Products

NDA 214520

2023-11-15

NDA

CORMEDIX INC

NDA 214155

2021-03-12

NDA

MELINTA THERAPEUTICS LLC

NDA 208610

2017-06-19

NDA

MELINTA SUBSIDIARY CORP

NDA 208611

2017-06-19

NDA

MELINTA SUBSIDIARY CORP

NDA 206334

2014-08-06

NDA

MELINTA THERAPEUTICS LLC